Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | POLB | P06746 | 4/20 | 1.00 |
| ▸ | RAB9A | P51151 | 3/20 | 0.67 |
| ▸ | NPC1 | O15118 | 3/20 | 0.67 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.61 |
| ▸ | MAPT | P10636 | 2/20 | 0.61 |
| ▸ | MEN1 | O00255 | 1/20 | 0.61 |
| ▸ | ATM | Q13315 | 1/20 | 0.61 |
| ▸ | TSHR | P16473 | 2/20 | 0.49 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.49 |
| ▸ | GLA | P06280 | 1/20 | 0.48 |
| ▸ | MGLL | Q99685 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3842872 | 0.85 | POLB (0.73) | POLBRAB9ANPC1KMT2AMAPT | |
| SCHEMBL29744041 | 0.79 | RAB9A (0.78) | POLBRAB9ANPC1KMT2AMEN1 | |
| SCHEMBL12804348 | 0.79 | RAB9A (0.78) | POLBRAB9ANPC1KMT2AMEN1 | |
| SCHEMBL17209560 | 0.78 | POLB (0.64) | POLBRAB9ANPC1KMT2AMAPT | |
| SCHEMBL3850746 | 0.78 | POLB (1.00) | POLBKMT2AMAPTMEN1KDM4E | |
| Indole-2-Carboxylic Acid SCHEMBL14158195 | 0.75 | RAB9A (0.72) | POLBRAB9ANPC1KMT2AMEN1 | |
| SCHEMBL14158447 | 0.75 | RAB9A (0.72) | POLBRAB9ANPC1KMT2AMEN1 | |
| SCHEMBL31416409 | 0.74 | KMT2A (0.62) | POLBRAB9ANPC1KMT2AMEN1 | |
| SCHEMBL29812976 | 0.74 | POLB (0.57) | POLBRAB9ANPC1KMT2AMAPT | |
| SCHEMBL5003022 | 0.73 | POLB (0.58) | POLBRAB9ANPC1KMT2AMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120276141-A1 | ENV POLYPEPTIDE COMPLEXES AND METHODS OF USE | SRIVASTAVA INDRESH K (US) | 2012-11-01 | — | — | US | claimed |
| US-8197819-B2 | Exposure of epitopes on envelop protein; complex of polypeptide and antigen; induce immunology response | NOVARTIS VACCINES AND DIAGNOSTICS, INC. (US) | 2012-06-12 | — | — | US | claimed |
| US-20120276141-A1 | ENV POLYPEPTIDE COMPLEXES AND METHODS OF USE | SRIVASTAVA INDRESH K (US) | 2012-11-01 | — | — | US | disclosed |
| US-20120276141-A1 | ENV POLYPEPTIDE COMPLEXES AND METHODS OF USE | SRIVASTAVA INDRESH K (US) | 2012-11-01 | — | — | US | disclosed |
| US-20120276141-A1 | ENV POLYPEPTIDE COMPLEXES AND METHODS OF USE | SRIVASTAVA INDRESH K (US) | 2012-11-01 | — | — | US | disclosed |
| US-8197819-B2 | Exposure of epitopes on envelop protein; complex of polypeptide and antigen; induce immunology response | NOVARTIS VACCINES AND DIAGNOSTICS, INC. (US) | 2012-06-12 | — | — | US | disclosed |
| US-8197819-B2 | Exposure of epitopes on envelop protein; complex of polypeptide and antigen; induce immunology response | NOVARTIS VACCINES AND DIAGNOSTICS, INC. (US) | 2012-06-12 | — | — | US | disclosed |
| US-8197819-B2 | Exposure of epitopes on envelop protein; complex of polypeptide and antigen; induce immunology response | NOVARTIS VACCINES AND DIAGNOSTICS, INC. (US) | 2012-06-12 | — | — | US | disclosed |
| EP-1773880-A4 | ENV POLYPEPTIDE COMPLEXES AND METHODS OF USE | NOVARTIS VACCINES & DIAGNOSTIC (US) | 2009-09-09 | — | — | EP | disclosed |
| US-20080199492-A1 | Env Polypeptide Complexes and Methods Of Use | NOVARTIS VACCINES AND DIAGNOSTICS INC. (US) | 2008-08-21 | — | — | US | disclosed |
| US-20080199492-A1 | Env Polypeptide Complexes and Methods Of Use | NOVARTIS VACCINES AND DIAGNOSTICS INC. (US) | 2008-08-21 | — | — | US | disclosed |
| US-20080199492-A1 | Env Polypeptide Complexes and Methods Of Use | NOVARTIS VACCINES AND DIAGNOSTICS INC. (US) | 2008-08-21 | — | — | US | disclosed |
| EP-1773880-A2 | ENV POLYPEPTIDE COMPLEXES AND METHODS OF USE | Novartis Vaccines and Diagnostics, Inc. (US) | 2007-04-18 | — | — | EP | disclosed |
| WO-2005121175-A9 | ENV POLYPEPTIDE COMPLEXES AND METHODS OF USE | CHIRON CORP (US) | 2006-03-16 | — | — | WO | disclosed |
| WO-2005121175-A2 | ENV POLYPEPTIDE COMPLEXES AND METHODS OF USE | NOVARTIS VACCINES AND DIAGNOSTICS INC. (US) | 2005-12-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080199492-A1 | Env Polypeptide Complexes and Methods Of Use | CD4, CD74, HAVCR2 | POLB 3936/4885RAB9A 2725/4885NPC1 2948/4885 |
| US-20120276141-A1 | ENV POLYPEPTIDE COMPLEXES AND METHODS OF USE | CD4, CD74, HAVCR2 | POLB 3936/4885RAB9A 2725/4885NPC1 2948/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.